Who Generates More Revenue? Vericel Corporation or Arrowhead Pharmaceuticals, Inc.

Biotech Revenue Battle: Vericel vs. Arrowhead

__timestampArrowhead Pharmaceuticals, Inc.Vericel Corporation
Wednesday, January 1, 201417500028796000
Thursday, January 1, 201538200051168000
Friday, January 1, 201615833354383000
Sunday, January 1, 20173140770963924000
Monday, January 1, 20181614232190857000
Tuesday, January 1, 2019168795577117850000
Wednesday, January 1, 202087992066124179000
Friday, January 1, 2021138287000156184000
Saturday, January 1, 2022243231000164365000
Sunday, January 1, 2023240735000197516000
Monday, January 1, 20243551000
Loading chart...

In pursuit of knowledge

Revenue Race: Vericel vs. Arrowhead Pharmaceuticals

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Vericel Corporation and Arrowhead Pharmaceuticals, Inc. have been vying for dominance. From 2014 to 2023, Vericel consistently outperformed Arrowhead in revenue, with a notable peak in 2023, reaching approximately $198 million. In contrast, Arrowhead's revenue surged in 2022, peaking at around $243 million, a 50% increase from the previous year. However, by 2023, Arrowhead's revenue slightly declined to $241 million. This fluctuation highlights the volatile nature of the biotech industry, where innovation and market dynamics can rapidly shift financial outcomes. Notably, data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to innovate, investors and industry watchers will be keenly observing their financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025